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Abstract 
Purpose: To explore the cardioprotective effects and potential mechanisms of Shenxiong Glucose 
Injection (SGI) in rat acute myocardial infarction (AMI).  
Methods: AMI model was created by ligating left anterior descending coronary artery. After 7 days’ 
consecutive intravenous administration of SGI, serum samples were used to conduct biochemical 
analysis while hearts were excised and processed for infraction size, enzyme activity, histopathology 
and qPCR studies. Intracellular Ca2+ {(Ca2+)i} overload in H9c2 cells was measured by laser scanning 
confocal microscope (LSCM). 
Results: In AMI rats, pretreatment with SGI significantly ameliorated myocardial histopathologic 
damage. It exerted cardioprotective effect by decreasing myocardial infarct size, electrocardiogram 
(ECG) ST segment elevation, and CK, cTnI, BNP levels in serum. In addition, SGI significantly 
decreased calmodulin (CaM) and calmodulin-dependent protein kinase II (CaMK II) mRNA expression, 
but increased Ca2+-Mg2+-ATPase and Na+-K+-ATPase activities in myocardium. In doxorubicin (DOX)-
induced H9c2 cells injury model, SGI reversed (Ca2+)i overload to protect cells. 
Conclusion: The results demonstrate SGI exerts cardioprotective effect by decreasing myocardial 
infarct size, restoring ST segment and reversing (Ca2+)i overload. It suggests that SGI may be a new 
clinical candidate to treat myocardial infarction. 
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Ischemic heart disease, commonly called 
coronary artery disease, is a disease 
characterized by reduced blood supply to the 
heart. It has been the top one cause of life loss 
each year all over the world, bringing about 8.14 
million fatalities in 2013 up from 5.74 million 
fatalities in 1990. It has been a tough global 
health problem to be solved according to the 
data analysis of cause-specific mortality for 240 
causes of death during 1990 - 2013[1]. Although 
kinds of drugs such as aspirin, thrombolysis 
agents, β receptor blockers and ACE inhibitors 
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have been used to treat AMI [2,3], AMI is still one 
of the major cause of ischemic heart diseases, 
and with high rate of morbidity and mortality [4]. 
Therefore, the safer and more effective drugs still 
need to be explored for clinical use. 
 
SGI is also known as Bai Se Tong, and its 
components are originated from danshen (Salvia 
miltiorrhiza Bge.) and chuanxiong (Ligusticum 
chuanxiong Hort.). It has been widely used in 
cerebral ischemia disease and other ischemic 
diseases in Asia. Tanshinol and ligustrazine 
hydrochloride, the active ingredients of SGI, have 
been confirmed to exhibit powerful protective 
effects on cardio-cerebrovascular disease in vitro 
and in vivo, and they have shown various 
pharmacological activities such as anti-oxidation, 
anti-apoptosis, and anticoagulation in the 
treatment of ischemic and infarction disease [5-
7].  
 
Previous studies have shown that SGI 
possesses protective effects on cerebral, and its 
potential mechanisms are involved in anti-
inflammation, anti-oxidation and anticoagulation 
[8]. And what’s more, clinical applications and 
animal experimental studies have demonstrated 
that there are seldom adverse effects after 
administration of SGI [8,9]. However, the 
cardioprotective effect and mechanisms of SGI 
has been rarely reported.  
 
The main objective of our study is to investigate 
the cardioprotective effects and potential 






SGI was provided by Guizhou Jingfeng Injection 
Co., Ltd. (Guiyang, China). Panax notoginseng 
saponins (PNS) was bought from Guangxi 
Wuzhou Pharmaceutical Co., Ltd. (Wuzhou, 
China). Kits for creatine kinase (CK), Ca2+-Mg2+-
ATPase and Na+-K+-ATPase were purchased 
from Nanjing Jiancheng Bioengineering Institute 
(Nanjing, China). Cardiac troponin I (cTnI) and 
brain natriuretic peptide (BNP) Elisa kits were 
obtained from Wuhan Cusabio Biotech Co., Ltd. 
(Wuhan, China). Fluo-3-AM was supplied by 
Beijing Fanbo biochemical pharmaceutical Co., 
Ltd. (Beijing, China). N-acetylcysteine (NAC) and 
DOX were provided by MP biochemical 
(California, USA). And kits for PrimeScript™ RT 
reagent Kit (Perfect Real Time) and SYBR® 
Premix Ex Taq™ II (Tli RNaseH Plus) were 
gained from Takara(Shenyang, China). H9c2 
cells were got from the Cell Bank of the Chinese 
Academy of Sciences (Shanghai, China). 
Animals and AMI injury model 
 
Adult specific pathogen free (SPF) male 
Sprague-Dawley (SD) rats (180-220 g, 
certificate: NO. SCXK (Guangdong) 2013-0034) 
were obtained from the Medical Laboratory 
Animal Research Center of Guangdong 
Province. All rats were kept in a SPF level 
laboratory animal room in the institution of 
Laboratory Animal Science of Jinan University 
with normal temperature and 12 h light-dark 
cycle. Rats were provided with standard 
laboratory diet and water. The experiments were 
approved by the Committee on Animal Care of 
Jinan University (no. 20140615231359) and were 
performed according to the instructions of the 
National Institute of Health (OLAW/NIH 2002) 
[10]. 
 
SD rats were randomly assigned into 6 groups 
with 14 rats in each group: sham-operated 
(control), AMI, PNS (22.30 mg/kg), Low-dose 
SGI (0.714 mg/kg tanshinol and ligustrazine 
hydrochloride 3.57 mg/kg), Middle-dose SGI 
(3.57 mg/kg tanshinol and ligustrazine 
hydrochloride 17.85 mg/kg), High-dose SGI 
(tanshinol 17.85 mg/kg and ligustrazine 
hydrochloride 89.25 mg/kg). PNS has been 
widely used in cerebral and myocardial ischemia 
disease in clinics. In this study, it was treated as 
a positive control. The rats of control and AMI 
groups were administered with 5 % of glucose 
injection via caudal vein for 7 days consecutively, 
while the rest of rats were administered for 7 
days respectively with the drugs accordingly. 
 
AMI injury model was created according to our 
previous study with slight modifications [11]. The 
rats were anesthetized with 25 % of urethanum 
(1 g/kg, intraperitoneally). Following intubation 
and artificial ventilation, the surgical operation 
was performed to expose heart. The heart was 
rapidly exposed and the left anterior descending 
coronary artery was ligated with a suture, control 
group just exposed heart without ligating. 
Electrocardiography was recorded by ECG2206B 
system (Nanjing Hengteng electronic technology 
Co., Ltd., Nanjing, China) before and 5, 15, 30, 
60, 120 min after the surgery, the ECG recording 
speed was 50 mm/s at a voltage of 10 mm/mV. 
The ST segment elevation of limb lead (II) ECG 
was used to determine the AMI injury. After the 
last time ECG recording, blood samples were 
collected from abdominal aorta to separate out 
serum by centrifugation at 3000 rpm for 10 min 
for further biochemical analysis. Successively, 
the hearts of all rats were got and performed for 
infraction size, pathology, and qPCR researches. 
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Measurement of serum biomarker of AMI 
 
The serum content of CK, cTn-I and BNP was 
measured by corresponding commercial 
enzyme-linked immunosorbent assay kits 
described above. Spectrophotometry method 
was used to detect the kits by multi-detection 
microplate reader (Synergy™ HT, BioTek, USA). 





Left ventricular heart tissues were fixed in 
paraformaldehyde and embedded in paraffin, 
and then slice into serial very thin pieces using 
microtome. The pieces were stained with H&E to 
observe the change of myocardium s by a 
microscope (Olympus CX31, Japan). 
 
Determination of infarct size 
 
The infarct size was determined as previously 
described [11]. The TTC-stained areas (red 
staining) and TTC-stained negative areas 
(myocardial infarction) were isolated and the 
infarct size was expressed as the percentage of 
the myocardial weight.  
 
Determination of Ca2+-Mg2+-ATPase and Na+-
K+-ATPase activities 
 
Myocardial tissues were weighed and made into 
homogenates with normal saline. After 
centrifugation, the supernatant was obtained and 
used to determinate the protein concentration 
and the enzyme activity. The procedure used 
were strictly in accordance with the instruction of 
ATPase assay kits and Bradford Protein Assay 
Kit. 
 
Measurement of mRNA expression of CaM 
and CaMK II 
 
RNA was obtained from the myocardial tissues. 
Myocardial tissues were grinded with liquid 
nitrogen. Later, mRNA was extracted by RNA 
Trizol reagent and RNA integrity was determined 
by 1 % of agarose gel. cDNAs were reversely 
transcribed using each RNA sample and were 
amplified by PCR. The primers sequences for rat 
CaM were: F:5’ GATAAGGATGGCAATGGC 
TACA3’ R:5’CGATGTCTGCTTCCCTGATCAT3’, 
CaMK II were: F:5’GTGATGGGAAGTGGCA 
GAATA3’ R: 5’CGTGGCACTGTTGACAATTAG 
A3’ and β-actin were: F:5’CCTGTGGCA 
TCCATGAAACTAC3’ R: 5’CTTCTGCATCCTG 
TCAGCAAT3’. β-actin was used as a reference 
gene. The mRNA relative expression levels of 
CaM and CaMK II were normalized to β-actin 
and calculated using the 2-ΔΔCT method. 
 
Measurement of intracellular calcium 
concentration 
 
Changes in (Ca2+)i concentration were measured 
by Ca2+ sensitive fluorescent indicator Fluo-3-AM 
and LSCM (LSM 510 META, Zeiss, Germany). 
H9c2 cells were cultivated with or without SGI 
(0.08, 0.28 and 0.48 μmol/L, calculated by 
ligustrazine hydrochloride), NAC(1 mmol/L) for 2 
h except control group, then added 1 μmol/L 
DOX cultivated for 48 h. The cells were quickly 
flushed and incubated with 5 μM Fluo-3-AM in a 
glass-bottom dish for 30 min at 37 °C and quickly 
flushed three times with PBS buffer and 
incubated for 15 min. (Ca2+)i was measured as 
described previously[12]. Fluorescence was 
excited at a wavelength of 490 nm and emitted 
light was observed at 525 nm. Zeiss LSM image 
browser, a data processing system, was used to 




All numerical results are presented as mean ± 
SEM and statistical significance was analyzed 
with one-way analysis of variance (ANOVA) 
using SPSS 17.0 software. Differences were 




SGI ameliorates ECG and decreases 
biomarkers of AMI injury in AMI rats 
 
The myocardial injury can lead to abnormal ST 
segment change, so ECG can reflect the 
myocardial injury directly. In our present study, 
AMI injury resulted in significant ST segment 
elevation in the AMI group, which demonstrated 
that the AMI injury model of rats was successfully 
established. In addition, compared with AMI 
group, the ST segments of other groups were 
significantly reduced in a dose and time-
dependent manner (Figure 1A). More 
importantly, the ST segment elevation of PNS 
and SGI (H) was significantly reduced within 120 
min of the experiment (p < 0.01 or 0.05). The 
ECG of rats at 120 min are shown in Figure 1B. 
What’s more, we also measured the content of 
CK, cTnI and BNP to examine the extent of 
myocardial damage and the protective effects of 
SGI. As shown in Table 1, the CK, cTnI and BNP 
contents of AMI group rats were higher than 
those for control group (p < 0.05). However, after 
being treated with SGI or PNS, the serum CK, 
cTnI and BNP contents were significantly 
decreased (p < 0.01 or 0.05).
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Figure 1: Effect of SGI on ECG in AMI injury rats. ST segment elevation in AMI injury rats during 120 min (A). 
ECG of AMI injury rats at 120 min (B). Compared with AMI group; *p <0.05, **p < 0.01, (n ≥ 12). The letters a to f 
are represented for control group, AMI group, PNS group, SGI(H) group, SGI(M) group and SGI(L) group, 
respectively 
 
       Table 1: Effect of SGI on serum CK, cTnI and BNP content in AMI injury rats 
 
Group CK (serum, U/mL) cTnI (serum, μg/L) BNP (serum, pg/mL) 
Control 0.90±0.06* 217.21±26.73* 1088.32±89.14* 
AMI 1.11±0.07 293.66±24.16 1364.94±79.80 
PNS 0.85±0.07* 317.23±42.13 1331.29±134.82 
SGI (H) 0.82±0.08* 168.11±13.19** 1259.32±131.70 
SGI (M) 0.88±0.06* 176.66±35.73* 1081.37±111.03* 
SGI (L) 0.72±0.06** 214.19±35.80 996.14±47.40** 
        Compared with AMI group, *p<0.05, **p<0.01, (n ≥ 7) 
 
SGI decreases infarct size and protects 
myocardium structure in AMI rats  
 
As shown in Figure 2B, myocardial infarct size in 
AMI group was significantly larger than that of 
control group (p < 0.01). When treated with SGI 
or PNS, myocardial infarct size was significantly 
reduced (p < 0.01 or p < 0.05), except SGI (L). 
TTC staining of myocardium intuitively revealed 
the degree of AMI injury of rats (Figure 2A, a–f). 
Meanwhile, histopathological analysis showed 
that myocardium structure of control group rats 
were normal with clear boundaries, but AMI 
injury in AMI group caused myocardium to be 
remarkably loose and disordered. Rats treated 
with PNS or SGI can ameliorate irregular 
arrangement of myocardium (Figure 2C, a–f). 
 
SGI regulates Ca2+ related enzyme activity 
and mRNA expression 
 
As shown in Table 2, rats suffered from AMI 
injury induced to significant decline of the Ca2+-
Mg2+-ATPase and Na+-K+-ATPase activities (p < 
0.01). PNS and SGI pretreatment protected their 
activities decline from AMI injury (p < 0.01 or p < 
0.05). Meanwhile, CaM and CaMK II expressions 
were significantly improved in AMI injury rats (p < 
0.01). On the contrary, pretreatment of PNS and 
SGI significantly decreased CaM and CaMK II 
mRNA expression in some degree (p < 0.01 or p 
< 0.05). 
 
SGI decreases DOX-induced H9c2 cells 
(Ca2+)i overload 
 
In order to confirm the effect of SGI on (Ca2+)i  
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overload, we investigated it in DOX-induced 
H9c2 cells injury model. Intuitively, the 
fluorescence intensity of DOX group was more 
severe than other groups (Figure 3A). Then, 35 
cells were randomly selected in each group to 
calculate the relative intracellular calcium 
concentration. The results show that (Ca2+)i of 
the DOX group was higher than that of the 
control group (p < 0.01). Similarly, (Ca2+)i of NAC 
group, all the SGI groups had a significantly 






Figure 2: Effect of SGI on infarct size and microscopic observation of cardiac tissue. The myocardial infarct size 
was measured by TTC staining (A). Quantitative analysis the myocardial infarct size of the AMI injury rats (B). 
Myocardium stained with H&E to observe myocardial injury (C) (×100). Compared with AMI group; *p < 0.05, **p < 
0.01, (n ≥ 4). The letters a to f are represented as describe above 
 
Table 2: Effect of SGI on Ca2+-Mg2+-ATPase, Na+-K+-ATPase activities and CaM , CaMK II mRNA relative 







CaM CaMK II 
Control 1.93±0.17** 2.01±0.14** 0.29±0.02** 0.66±0.03** 
AMI 0.89±0.17 1.14±0.09 1.00±0.24 1.00±0.03 
PNS 1.69±0.14** 1.85±0.16** 0.35±0.09** 0.80±0.01* 
SGI(H) 1.66±0.13** 1.84±0.22** 0.35±0.02** 0.80±0.17* 
SGI(M) 1.38±0.14** 1.57±0.24* 0.65±0.03** 1.00±0.08 
SGI(L) 1.33±0.09** 1.54±0.12* 0.75±0.07** 1.01±0.02 




SGI, consisted of two effective ingredients 
ligustrazine hydrochloride and tanshinol, has 
shown multiple effects on cerebral disease, but 
the cardioprotective effect and mechanisms of 
SGI has been rarely reported [8]. The objective 
of our present study is to examine whether SGI 
plays a protective role in AMI injury and explore 
its potential mechanisms. 
 
ECG and the content of CK, cTnI and BNP have 
been widely used as biomarkers of myocardial 
injury. Consistent with the previous studies [11], 
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Figure 3: Treatment of SGI inhibited DOX-induced (Ca2+)i overload. (Ca2+)i was determined with Fluo-3-AM 
probe by LSCM (scale bar: 100 μm) (A). Quantitative analysis of relative (Ca2+)i concentration (B). Compared 
with DOX group, *p < 0.05, **p < 0.01. a: Control group, b: DOX group, c: 1 mmol/L NAC group, d: 0.08 μmol/L 
SGI group, e: 0.28 μmol/L SGI group, f: 0.48 μmol/L SGI group 
 
we observed significant increase of CK, cTnI and 
BNP content and elevation of typical ECG ST 
segment in rats subjected to acute myocardial 
infarction. The pretreatment of SGI can decline 
the high level of CK, cTnI, BNP and the elevation 
of ECG ST segment. Meanwhile, we also found 
that the area at risk was significantly reduced 
and myocardial structure was better-preserved in 
SGI pretreatment rats. All in all, these results 
have demonstrated the cardioprotective effects 
of SGI. 
 
As an important second messenger, Ca2+ signal 
is a leading mediator in the management of 
many physiological and cellular activities, such 
as muscle contraction, metabolism, cell necrosis, 
apoptosis and autophagy and so on [13,14]. In 
ischemic and infarcted myocardium, the 
deficiency of ATP triggers the lower activity of 
Ca2+-Mg2+-ATPase and Na+-K+-ATPase, which 
induces Na+ overload and secondary Ca2+ influx. 
(Ca2+)i overload can cause arrhythmia and 
necrosis during myocardial infarction [15]. The 
overwhelming (Ca2+)i combines with CaM and 
further activates CaMK II, which can regulate 
Ca2+ concentration by changing the function of 
ryanodine receptor (RyR), phospholamban (PLB) 
and L type calcium channel (LTCC) [16,17]. On 
the one hand, CaMK II can improve the (Ca2+)i 
concentration by prolonging the opening time of 
RyR and LTCC. On the other hand, it can 
phosphorylate PLB, further relieve the inhibition 
on Ca2+-ATPase and enhance the Ca2+ reuptake 
of the sarcoplasmic reticulum (SR). As outlined 
above, CaMK II, as a significant regulator of 
(Ca2+)i, has been confirmed as a therapeutic 
target in new drug research and development, 
and studies have demonstrated that blocking 
CaMK II with inhibitor KN93 can significantly 
diminish ischemic contracture in vivo, prevent 
cardiomyocyte mortality, and make SR Ca2+ 
release lower to ameliorate myocardial infarct 
size in ischemia-reperfusion rats [18,19]. The 
overload of (Ca2+)i concentration also causes the 
dysfunction of mitochondrial, increases 
concentration of oxygen free radicals and leads 
to myocardial cell death. Furthermore, clinical 
AMI cause sympathetic activation and 
catecholamine levels to rise, while catecholamine 
can increase the influx of Ca2+ through PKA 
pathway by activating α and β receptors [20,21]. 
 
Some studies have demonstrated that Danshen 
and its components have effects on calcium 
channels in ventricular myocytes and coronary 
artery [22,23]. Similarly, ligustrazine, defined as a 
calcium antagonist, not only will it block the entry 
of extracellular calcium but it will also inhibit the 
release of intracellular calcium. Moreover, it can 
also open potassium channel to make calcium 
influx lower [24,25]. According to the results, we 
found that SGI can reduce DOX-induced H9c2 
cells damage by decreasing Ca2+ overload in 
vitro. In order to verify such effect in vivo, we 
investigated its myocardial protective effect in the 
left anterior descending coronary artery 
occlusion-induced AMI injury experiment. The 
results shown that SGI significantly improved the 
activities of Ca2+ related enzymes and decreased 
the mRNA expression of CaM and CaMK II in a 
dose-dependent manner. 
 
The results indicate that SGI might protect 
cardiomyocytes from AMI injury by decreasing 
(Ca2+)i overload through inhibiting CaM/CaMK II 
pathway and improving the activities of Ca2+-




SGI protects cardiomyocytes against AMI by 
decreasing the infarction size, ameliorating 
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myocardial histopathological damage, improving 
the activities of Ca2+-Mg2+-ATPase and Na+-K+-
ATPase, and reducing (Ca2+)i overload through 
inhibition of CaM/CaMK II pathway, This 
suggests that SGI may be a new clinical 
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